Age 12–45 males with FXS with a molecular genetic confirmation FMR1 >200 CGG repetitions needed for clinical trials of new drug zatolmilast.
Tetra Therapeutics is conducting a two randomized, placebo-controlled studies of BPN14770 (zatolmilast) to learn about the experimental drug’s safety and efficacy. Both trials will be followed by an open label extension study. If results are positive, Tetra will be seeking approval of the drug with the FDA.
About the Study
Who can participate?
Males ages 12–45 may be eligible to participate with a molecular genetic confirmation of FXS: FMR1 >200 CGG repetitions.
What will happen in the study?
If the individual qualifies and decides to be in this research study, they will conduct eight visits (at clinic and at home) over 13 weeks.
The following is a list of some of the study procedures that will happen during the study:
- Participant cognitive and behavior testing
- Blood draws
- Parent/caregiver questionnaires
For more information, check out Tetra’s study flyer or visit Tetra’s website.
What are the good things that can happen from this research?
Potential benefits are improvement in cognitive (language and vocabulary) function and improvement in daily activities/behavior.
What are the bad things that can happen from this research?
Potential drug side effects include mild nausea and diarrhea.
There may be other risks that we do not know about yet.
Will I or my child be paid to complete this study?
Participants receive $50 per visit (6).
Travel reimbursement is available for eligible families.
Who can I contact for more information about this study?
There will be several sites across the U.S. Complete the contact form below to be notified when they open!
Interested in Participating?
Our Most Recent Opportunities
IMPACT-FXS: Investigating Multiple Pathways And Combined Treatments for FXS
Healx is conducting a Phase 2, placebo-controlled study in adolescent and adult males with fragile X syndrome (FXS). The purpose of this study is to confirm whether Healx's drug candidates are safe and work as intended to reduce symptoms of FXS.
Survey: Developing a Gold Standard for Tracking Adult Functional Outcomes in Developmental Disabilities (AFS Study)
University of Pittsburgh is conducting this research to develop the Adult Functioning Scale (AFS), a new survey being designed to capture outcomes in the areas of social functioning, employment, independence, and satisfaction for individuals with various developmental disorders.
Study: Aging in Toolbox
Researchers around the country are conducting a study to better understand cognitive profiles in adults with intellectual disability. This study is an extension of the ongoing Toolbox Study, which is aimed to optimize cognitive assessment tools for children and young adults with intellectual disabilities.
Validation of Fragile X-Associated Tremor Ataxia Syndrome Rating Scale (FXTAS-RS)
Rush University is conducting a research study to validate a rating scale created to assess the motor symptoms of people with FXTAS – the “Fragile X-Associated Tremor Ataxia Syndrome Rating Scale (FXTAS-RS)”
Study: Connection between Cognition and Genetic Factors in Adults with FXS
Drs. Craig Erickson and Lauren Schmitt at Cincinnati Children’s Hospital are conducting a series of research studies to learn about the brain and cognition and how they are connected with genetic factors related to FXS.
Study: UNC Brain Development Research Study of Infants with Fragile X Syndrome
UNC Chapel Hill is conducting a research study to learn about the early brain and behavioral development of infants with FXS to aid in the future development of better supports and treatments.